Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 5/20 | 0.42 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851945 | 0.98 | RECQL (0.61) | RECQLTET2KDM4ELMNAGAA | |
| Hydrochloric Acid SCHEMBL13837362 | 0.96 | RECQL (0.55) | RECQLTET2KDM4ELMNAGAA | |
| SCHEMBL30046593 | 0.93 | RECQL (0.57) | RECQLTET2KDM4ELMNAGAA | |
| SCHEMBL18820682 | 0.83 | RECQL (0.45) | RECQLTET2KDM4ELMNAGAA | |
| SCHEMBL27646874 | 0.81 | RECQL (0.41) | RECQLTET2KDM4ELMNAGAA | |
| Hydrochloric Acid SCHEMBL265730 | 0.81 | GAA (0.61) | RECQLLMNAGAAMGAMSI | |
| Hydrochloric Acid SCHEMBL715683 | 0.81 | RECQL (0.39) | RECQLTET2KDM4ELMNAGAA | |
| SCHEMBL18753028 | 0.80 | RECQL (0.69) | RECQLTET2KDM4ELMNAGAA | |
| SCHEMBL2414615 | 0.79 | RECQL (0.61) | RECQLTET2KDM4EGAAMGAM | |
| SCHEMBL9512043 | 0.79 | RECQL (0.40) | RECQLTET2KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120037719-A | High-precision wear-resistant filter material coated with nano coating and preparation method thereof | 江苏奥凯环境技术有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-107056673-A | 3, 4-diaryl maleimide derivative and preparation method and application thereof | 南京工业大学 | 2017-08-18 | — | — | CN | claimed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-120037719-A | High-precision wear-resistant filter material coated with nano coating and preparation method thereof | 江苏奥凯环境技术有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119823106-A | Enhanced nucleic acid polymerization by aromatic compounds | 豪夫迈·罗氏有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250059159-A1 | PLPRO INHIBITORS | HUAHAI US INC. | 2025-02-20 | — | — | US | disclosed |
| CN-114144520-B | Enhanced nucleic acid polymerization by aromatic compounds | 豪夫迈·罗氏有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4448515-A1 | PLPRO INHIBITORS | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-1219551-C | Conjugates made of metal complexes and oligonucleotides | SCHERING AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-0777498-B1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| CN-1152879-A | Conjugates made of metal complexes and oligonucleotides | SCHERING AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| EP-0777498-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996002274-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| US-4711952-A | IMMUNOSTIMULATIVE, OR IMMUNOSUPPRESSORY AGENTS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOUVYROBU (CS) | 1987-12-08 | — | — | US | disclosed |
| EP-0232435-A2 | Serum thymic factor peptide analogs and a process for the preparation thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | GAA 4052/4885GLA 2450/4885CA2 1427/4885 |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | GAA 323/4885GLA 1801/4885CA2 1234/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | GAA 3472/4885GLA 2863/4885CA2 2564/4885 |
| US-20250059159-A1 | PLPRO INHIBITORS | SARS1, PLP2, PLPBP | GAA 741/4885GLA 763/4885CA2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.